TY - JOUR
T1 - Relationship between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs)
T2 - findings from the Living with MPN patient survey
AU - Yu, Jingbo
AU - Paranagama, Dilan
AU - Geyer, Holly L.
AU - Parasuraman, Shreekant
AU - Mesa, Ruben
N1 - Funding Information:
Conflict of interest JY, DP, and SP are employees and shareholders of Incyte Corporation. RM received research funding from Celgene, CTI, Gilead, Incyte Corporation, and Promedior and served as a consultant for Ariad, Galena, and Novartis. HLG has no conflicts to disclose.
Funding Information:
Acknowledgments Medical writing assistance was provided by Jane Kovalevich, PhD (Complete Healthcare Communications, LLC, North Wales, PA, a CHC Group company) and was funded by Incyte Corporation.
Funding Information:
This work was funded by Incyte Corporation.
Publisher Copyright:
© 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2019/5/1
Y1 - 2019/5/1
N2 - Patients with myeloproliferative neoplasms (MPNs) experience burdensome symptoms that negatively affect their quality of life. How MPN symptoms relate with medical disability leave (MDL) among patients with the disease has not been previously examined. Using data collected from the Living with MPNs patient survey, symptom burden and functional status were compared in patients who reported taking MDL due to their MPN versus patients who reported no changes in employment status. Among 592 patients who were employed full- or part-time at diagnosis, 24.8% reported taking ≥ 1 MDL and 49.4% reported no change in employment status as a result of their MPN. Of the patients who took MDL, 29.9% took ≥ 2 MDLs, and most patients (62.6%) did not return to work. All 10 symptoms comprising the MPN Symptom Assessment Form were significantly more frequent and severe in patients who took MDL compared with those who had no employment change. Furthermore, functional impairments were also significantly more frequent among patients who went on MDL versus those with no employment change. Effective management of MPN-related symptoms may reduce disability leave among patients with high symptom burden.
AB - Patients with myeloproliferative neoplasms (MPNs) experience burdensome symptoms that negatively affect their quality of life. How MPN symptoms relate with medical disability leave (MDL) among patients with the disease has not been previously examined. Using data collected from the Living with MPNs patient survey, symptom burden and functional status were compared in patients who reported taking MDL due to their MPN versus patients who reported no changes in employment status. Among 592 patients who were employed full- or part-time at diagnosis, 24.8% reported taking ≥ 1 MDL and 49.4% reported no change in employment status as a result of their MPN. Of the patients who took MDL, 29.9% took ≥ 2 MDLs, and most patients (62.6%) did not return to work. All 10 symptoms comprising the MPN Symptom Assessment Form were significantly more frequent and severe in patients who took MDL compared with those who had no employment change. Furthermore, functional impairments were also significantly more frequent among patients who went on MDL versus those with no employment change. Effective management of MPN-related symptoms may reduce disability leave among patients with high symptom burden.
KW - Disability leave
KW - Essential thrombocythemia
KW - Myelofibrosis
KW - Myeloproliferative neoplasm
KW - Polycythemia vera
UR - http://www.scopus.com/inward/record.url?scp=85061023839&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061023839&partnerID=8YFLogxK
U2 - 10.1007/s00277-019-03610-4
DO - 10.1007/s00277-019-03610-4
M3 - Article
C2 - 30694363
AN - SCOPUS:85061023839
SN - 0939-5555
VL - 98
SP - 1119
EP - 1125
JO - Annals of Hematology
JF - Annals of Hematology
IS - 5
ER -